What is the latest price information for Acalabrutinib in 2025?

Acalabrutinib is a highly selective Bruton's tyrosine kinase (BTK) inhibitor that is primarily used to treat certain types of hematological malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It effectively controls the growth of malignant tumors by selectively inhibiting BTK and inhibiting the proliferation and survival of B cells. Since its launch, acotinib has quickly occupied a place in tumor treatment due to its fewer side effects and better efficacy.

In2025, the price of acotinib will vary depending on region, medical insurance policy and whether it is an original drug. In China, acotinib has been approved and included in medical insurance, greatly reducing the financial burden on patients. According to the current market situation, the common specifications of acotinib in China are 100mg capsules of 8 capsules and 7 tablets (56 capsules in total), and the market price of each box is about RMB 20,000. It is important to note that prices may fluctuate depending on region, drug supplier, and sales channel. .

In overseas markets, the original drug price of acotinib is relatively high, but with the emergence of generic drugs, the price has gradually dropped. For example, the generic acotinib produced by Laos Pharmaceuticals has a specification of 100mg*60 capsules, and the price per box is about more than 2,000 yuan (exchange rate changes may affect the price). Although generic drugs are more affordable, their efficacy and side effects are similar to those of brand-name drugs, providing patients with more economical choices.

The price of acotinib is closely related to treatment needs, drug supply, and medical insurance policies. Patients should consider the source, quality, and personal financial situation of the drug when choosing. Overall, the global price differences of acotinib provide patients with different treatment options, especially with the launch of generic drugs, the cost of treatment is gradually reduced and more patients can afford the drug.

Reference materials:https://www.calquence.com/